HCC patients with higher expression of BARD1 had significantly decreased progression-free survival (PFS) and overall survival (OS) (PFS ~35 months; OS ~40 months) compared to lower BARD1 expression in their tumors (PFS ~53 months; OS ~57 months). Here, BARD1 is linked to hepatocellular carcinoma.